CENTER FOR BREAKTHROUGH MEDICINES AT DISCOVERY LABS
DEAD

Serial Number

97079346

Owner

MORNING LIGHT IP, LLC

Attorney

Joshua M. Gerben, Esq.

Filing Date

Oct 18, 2021

Add to watchlist:

No watchlists yet
View on USPTO

CENTER FOR BREAKTHROUGH MEDICINES AT DISCOVERY LABS Trademark

Serial Number: 97079346

CENTER FOR BREAKTHROUGH MEDICINES AT DISCOVERY LABS is a trademark filed by MORNING LIGHT IP, LLC on October 18, 2021. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

MORNING LIGHT IP, LLC (27 trademarks)

201 KING OF PRUSSIA ROAD
RADNOR, PA 19087

Entity Type: 16

CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC (19 trademarks)

411 SWEDELAND ROAD
KING OF PRUSSIA, PA 19406

Entity Type: 16

Trademark Details

Filing Date

October 18, 2021

Registration Date

Not Registered

Goods & Services

Manufacturing services for others in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting

Research and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services, namely, production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Oct 3, 2022 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Oct 1, 2022 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 18, 2022 GNRN
NON-FINAL ACTION E-MAILED
Mar 18, 2022 GNRT
NON-FINAL ACTION WRITTEN
Mar 18, 2022 CNRT
ASSIGNED TO EXAMINER
Mar 4, 2022 DOCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jan 26, 2022 ASGN
NOTICE OF DESIGN SEARCH CODE E-MAILED
Nov 5, 2021 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 4, 2021 NWOS
NEW APPLICATION ENTERED
Oct 21, 2021 NWAP